A Study to Evaluate YH001 in Subjects With Advanced Solid Tumors
A Open-Label, Phase I Dose Escalation Study to Evaluate the Safety, Tolerability,Efficacy and Pharmacokinetics of YH001 in Subjects With Advanced Solid Tumors
Sponsor: Eucure (Beijing) Biopharma Co., Ltd
This PHASE1 trial investigates Advanced Solid Tumors and is currently completed. Eucure (Beijing) Biopharma Co., Ltd leads this study, which shows 7 recorded versions since 2021 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Sep 2022 — Jan 2023 [monthly]
Recruiting PHASE1
-
Jun 2022 — Sep 2022 [monthly]
Recruiting PHASE1
▶ Show 2 earlier versions
-
May 2021 — Jun 2022 [monthly]
Recruiting PHASE1
-
Feb 2021 — May 2021 [monthly]
Recruiting PHASE1
First recorded
Jan 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eucure (Beijing) Biopharma Co., Ltd
For direct contact, visit the study record on ClinicalTrials.gov .